SCHEMBL6539002

SCHEMBL6539002

CC(C)n1nc(-c2cc(C#N)c(C(N)=O)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.37
KDM5A P29375 6/20 0.37
KDM6B O15054 1/20 0.37
KDM5C P41229 1/20 0.37
KDM5D Q9BY66 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
PHF8 Q9UPP1 1/20 0.37
TP53 P04637 1/20 0.36
POLB P06746 2/20 0.36
DGAT1 O75907 1/20 0.36
MAPT P10636 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
AURKA O14965 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
PLK1 P53350 1/20 0.34
CCNA1 P78396 1/20 0.34
MAP2K3 P46734 1/20 0.34
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538844 0.92 TP53 (0.37) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL6539015 0.89 KDM5A (0.42) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL6538517 0.86 AKT1 (0.39) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL6537897 0.84 NPSR1 (0.47) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL5149107 0.82 TP53 (0.37) RETKDM5AKDM6BKDM5CKDM5D
SCHEMBL6538925 0.82 AKT1 (0.42) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL5147991 0.82 TP53 (0.37) RETKDM5AKDM6BKDM5CKDM5D
SCHEMBL6538474 0.80 RET (0.41) RETTP53POLBMAPTMAP2K3
SCHEMBL6538335 0.79 CASP1 (0.42) RETTP53POLBMAPTKDM4E
SCHEMBL21904780 0.78 POLB (0.43) TP53POLBMAPTTDP1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 RET 4137/4885KDM5A 2156/4885KDM6B 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.